Perioperative stromal depletion by PEGPH20 in pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Ko, Andrew H.
Cinar, Pelin
Tempero, Margaret A.
Nakakura, Eric K.
Yeh, Benjamin M.
Chondros, Dimitrios
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Pancreas Ctr, San Francisco, CA 94143 USA
[5] Halozyme Therapeut, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS476
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PEGPH20 for metastatic pancreatic ductal adenocarcinoma
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (02): : E81 - E81
  • [2] Efficacy of pegvorhyaluronidase alfa (PEGPH20) plus FOLFIRINOX in a preclinical model of human pancreatic ductal adenocarcinoma.
    Bahn, Jesse
    Gao, Feng
    Li, Xiaoming
    Zimmerman, Susan
    Chen, Kelly
    Zhao, Chunmei
    Maneval, Daniel C.
    Thompson, Curtis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Pancreatic Cancer: PEGPH20 without Impact
    Kessing, Richard
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (01): : 22 - 22
  • [4] Musculoskeletal adverse events with PEGPH20 treatment and management in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    Andrew, Hendifar
    Piet, Vervaet
    Wilson, Wu
    Joaquina, Baranda
    Andrea, Bullock
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Photodynamic Stromal Depletion in Pancreatic Ductal Adenocarcinoma
    Lintern, Nicole
    Smith, Andrew M.
    Jayne, David G.
    Khaled, Yazan S.
    CANCERS, 2023, 15 (16)
  • [6] Musculoskeletal Events (MSEs) with PEGPH20 treatment and management in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDA)
    Bullock, A.
    Vervaet, P.
    Wu, W.
    Chondros, D.
    Hingorani, S. R.
    Hendifar, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Development of a companion diagnostic assay for tissue hyaluronan detection and treatment with PEGPH20 in metastatic pancreatic ductal adenocarcinoma patients.
    Khelifa, Sihem
    Pu, Jie
    Aldrich, Carrie
    Zhu, Junming
    Walker, Erika
    Zhilina, Zhanna
    Vladich, Frank
    Delgado, Paco
    Qadan, Ammar
    Mueller, Thomas
    Jiang, Ping
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC).
    Taverna, Darin
    Printz, Marie
    LaBarre, Michael J.
    Sekulovich, Rose E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] NURSING CONSIDERATIONS FOR PATIENTS RECEIVING PEGPH20, A NOVEL TREATMENT APPROACH TARGETING THE TUMOR MICROENVIRONMENT (TME) IN METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDA).
    Kirk, Christina
    Shelby, Lindsay
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
  • [10] Identification of differentially expressed genes in the stromal tissue of pancreatic ductal adenocarcinoma.
    Gruetzmann, Robert
    Ammerpohl, Ole
    Luettges, Jutta
    Kalthoff, Holger
    Wellmann, Axel
    Braunschweig, Till
    Kloeppel, Guenter
    Saeger, Hans Detlev
    Pilarsky, Christian
    CANCER RESEARCH, 2006, 66 (08)
12345